SHSylvia Haas

Sylvia Haas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sylvia Haas has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk

    by Sylvia Haas, Christoph Bode, Bo Norrving, Alexander G G Turpie

    Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K antagonists, including a rapid onset of action, few drug interactions, no dietary interactions, a predictable anticoagulant effect, and no requirement for routine coagulation monitoring. However, questions have emerged relating to the responsible use of rivaroxaban in day-to-day clinical practice, including patient selection, dosing, treatment of patients with renal impairment, conversion from use of vitamin K antagonists to rivaroxaban and vice versa, coagulation tests, and management of patients requiring invasive procedures or experiencing bleeding or an ischemic event. This article provides practical recommendations relating to the use of rivaroxaban in patients with nonvalvular atrial fibrillation, based on clinical trial evidence, relevant guidelines, prescribing information, and the authors' clinical experience.


  • Thromboseprophylaxe in der Chirurgie

    by S. Haas, A. Encke, R. Krauspe, C. Waydhas

    Physikalische und medikamentöse Maßnahmen der Thromboembolieprophylaxe gehören zur täglichen Routine in allen chirurgischen Fachdisziplinen. Die Indikationsstellung und Wahl der Prophylaxeform erfolgen in Abhängigkeit vom individuellen Risikoprofil des Patienten, welches durch Kombination von expositionellen und dispositionellen Risikofaktoren bestimmt wird. Das expositionelle Risiko ist durch Art und Umfang des chirurgischen Eingriffs bzw. Traumas geprägt, wogegen das dispositionelle Risiko patientenbezogene Risikofaktoren beinhaltet. Dies wurde auch bei der Erstellung von Leitlinien berücksichtigt. Die vorliegende Übersichtsarbeit fasst die Empfehlungen der Thromboembolieprophylaxe der Deutschen S3-Leitlinie für die Chirurgie zusammen und kommentiert den perioperativen Umgang mit Patienten, die zur Langzeitantikoagulation neue orale Antikoagulanzien (Rivaroxaban, Apixaban, Dabigatran) erhalten. Prevention of venous thromboembolism has become routine in all surgical disciplines and consists of physical and pharmacological measures. The indications and choice of prophylaxis modality depend on the individual patient risk profile which is determined by the combination of exposing and predisposing risk factors. The exposing risk factors are characterized by the type and extent of surgery or trauma, whereas the predisposing risk factors relate to patient-inherent risk factors. This is also taken into consideration for the compilation of guidelines. This review summarizes the recommendations of the German S3 guidelines related to surgery and also discusses the perioperative management of patients receiving long-term anticoagulation with new oral anticoagulants (rivaroxaban, apixaban, dabigatran).


  • Thromboembolieprophylaxe in der Unfallchirurgie

    by Dr. S. Haas, S. Siebenlist, C. Waydhas, R. Krauspe, U. Stöckle


  • Open Access

    Rivaroxaban – an oral, direct Factor Xa inhibitor – lessons from a broad clinical study programme

    by Sylvia Haas

    Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE), prevention of stroke in patients with atrial fibrillation (AF) and secondary prevention in patients with acute coronary syndrome (ACS). There is a clinical need for novel anticoagulants offering improvements over current standard of care, such as fixed oral dosing and no need for routine monitoring. Rivaroxaban, an oral, once-daily, direct Factor Xa inhibitor, has recently completed the RECORD phase III programme for the prevention of VTE in patients undergoing total hip or knee replacement (THR or TKR), an indication for which it is approved in Europe and Canada. It is being investigated in large-scale phase III studies for VTE treatment and prevention of stroke in patients with AF, and phase III studies will soon commence for secondary prevention in patients with ACS. Phase I studies demonstrated that no routine anticoagulation monitoring was required, while phase II studies suggested that fixed daily doses had a wide therapeutic window. The four RECORD studies consistently showed that rivaroxaban was significantly more effective than enoxaparin in the prevention of VTE after THR and TKR, with a similar safety profile. This review describes the development of this novel anticoagulant, from bench to bedside.


  • New anticoagulants – towards the development of an "ideal" anticoagulant

    by S Haas

    Currently available anticoagulants, such as unfractionated heparin, low molecular weight heparins and vitamin K antagonists, have proved effective in the prevention and treatment of thromboembolic disorders. However, these drugs have some drawbacks, such as unpredictability (in the case of unfractionated heparin), non-specificity and parenteral mode of administration, which limit their use in the clinical setting. There is a need for new agents with efficacy similar to that of these classes of anticoagulants and none of their associated drawbacks. Advances are being made in the development of more convenient and more specific drugs, with the aim to improve substantially the prevention and management of thromboembolic disorders. This review will emphasize how the development of an ideal anticoagulant, with potential benefits including high efficacy, safety, low levels of bleeding, fixed dosing, rapid onset of action, ability to bind clot-bound coagulation factors and no requirement for therapeutic monitoring, is a considerable challenge. This review will present the most relevant preclinical data, as well as the clinical studies performed to date, for several drug classes. Direct thrombin inhibitors, such as dabigatran etexilate, will be reviewed, as well as indirect (fondaparinux and idraparinux) and direct (rivaroxaban, apixaban, among others) Factor Xa inhibitors, Factor IXa inhibitors and monoclonal antibodies against Factor IX/IXa.


  • Thromboseprophylaxe bei chirurgischen und nicht chirurgischen Patienten

    by R. Bauersachs, S. Haas

    Eine routinemäßige Thromboseprophylaxe ist fester Bestandteil der Versorgung chirurgischer und orthopädischer Patienten und gewinnt bei internistischen Patienten an Bedeutung. Trotzdem sind Fragen zur Indikation, zu Art und Umfang der Prophylaxe sowie zu den Möglichkeiten der Verbesserung offen. Zur Indikationsstellung hat sich eine klinisch orientierte Risikoabschätzung bewährt, die expositionelle und dispositionelle Risikofaktoren berücksichtigt. Das expositionelle Risiko ist durch Art und Umfang des chirurgischen Eingriffs bzw. des Traumas charakterisiert, das dispositionelle Risiko hingegen durch patientenbezogene Faktoren. Dies wird auch in nationalen und internationalen Leitlinien beschrieben. Die Wahl der Prophylaxe resultiert aus der Kombination der expositionellen und dispositionellen Risikofaktoren. Zur VTE-Prophylaxe stehen physikalische und medikamentöse Maßnahmen zur Verfügung. Die tragenden Säulen der medikamentösen Prophylaxe waren bisher einmal tägliche subkutane Verabreichungen von niedermolekularen Heparinpräparaten oder Fondaparinux. Seit kurzem stehen für Hochrisikopatienten mit elektiven Hüft- oder Kniegelenkersatzoperationen auch orale direkte Thrombin- und Faktor- Xa-Inhibitoren zur Verfügung. Prevention of deep vein thrombosis has become standard of care in surgical and orthopaedic patients and it is gaining in attention in medical patients. However, there are still open questions related to its indication, to type and extent of prophylaxis and how to improve its efficacy and safety. In order to facilitate decision making to provide or to withhold prophylaxis, clinical risk assessment considering exposing and predisposing risk factors has proved to be of value. The exposing risk is characterised by type and extent of surgery or trauma, respectively, whereas the predisposing risk is determined by patient related risk factors. This has also been acknowledged in national and international guidelines. The choice of prophylactic modalities should be based on the combination of exposing and predisposing risk factors. Physical and pharmacological methods are available for primary prevention of VTE. The cornerstones of pharma -cological prophylaxis have been subcutaneous injections of low molecular weight heparins or fondaparinux. Recently, also oral direct thrombin- and factor Xa-inhibitors have become available for patients undergoing hip or knee replacement surgery who always are at high risk for VTE complications . * Diese Arbeit enthält wesentliche Teile einer CMEBeilage des Springer-Verlags. Die Publikation erfolgt mit freundlicher Genehmigung des Springer-Verlags, Heidelberg.


  • Primary Prevention of Venous Thromboembolism in Long-Term Care: Identifying and Managing the Risk

    by Sylvia Haas, Alex C. Spyropoulos

    Venous thromboembolism (VTE) is a significant, but underestimated, cause of morbidity and mortality in long-term care settings. VTE risk increases significantly with age and is further increased by comorbidities common to this group; however, advancing age and limited mobility alone are insufficient to warrant pharmacological prophylaxis. Recognizing those at increased VTE risk during an acute illness is crucial for appropriate and timely prophylaxis. Warfarin is used for the long-term secondary prevention of VTE, whereas unfractionated and low-molecular-weight heparins are used for primary prophylaxis. The elderly are at increased risk for bleeding complications, because of the high frequency of comorbidities and comedications. Attention to dosing is recommended for those with severely impaired renal function, low body weight, or perceived to be at high bleeding risk. This review addresses the role of risk assessment in the decision of when to provide prophylaxis to an individual in long-term care and highlights key management issues for those prescribed prophylaxis.


  • New oral Xa and IIa inhibitors: updates on clinical trial results

    by Sylvia Haas

    Heparins and VKAs have been the cornerstones of anticoagulation therapy for several decades and these agents have become most important drugs in the primary and secondary prevention of venous and arterial thromboembolic disease. Although effective, their use has been hampered by numerous limitations. In the search for new agents matching the ‘ideal’ anticoagulant profile, a number of different steps in the coagulation cascade have been targeted, including direct thrombin inhibition, and direct inhibition of Factor Xa. There are currently a host of promising new agents at various stages of development and clinical evaluation. With potential benefits including predictable efficacy, rapid onset of action, ability to bind clot-bound coagulation factors and no requirement for therapeutic monitoring, these new agents are set to improve the management of thromboembolic disorders.